Navigation Links
Tibotec Advances Global Clinical Research Program for TMC435 in HCV; Will Present Four Abstracts Evaluating Safety and Efficacy at EASL
Date:3/29/2011

CORK, Ireland, March 29, 2011 /PRNewswire/ -- Tibotec Pharmaceuticals announced today that four abstracts reporting research findings with TMC435, the company's investigational hepatitis C protease inhibitor, have been accepted for presentation at the 46th Annual Meeting of the European Association for the Study of the Liver (EASL) in Berlin, Germany, March 30 to April 3, 2011.  

The four abstracts for TMC435 support Tibotec's continued efforts to advance its research and development program for the treatment of HCV.  TMC435 highlights at the meeting include one oral presentation and one late-breaker poster presentation:

  • Analysis of the predictive nature of IL28B genotype and pretreatment serum IP-10 in treatment-naive HCV patients from phase IIb PILLAR study on TMC435 administered with pegIFN/ribavirin
  • Results from interim 24 week data of the international phase IIb randomized, double-blind, placebo-controlled ASPIRE study on efficacy, tolerability, safety, and pharmacokinetics of TMC435 administered with pegIFN/ribavirin in treatment-experienced HCV patients

  • "Tibotec is committed to developing innovative new treatment options that may offer better treatment outcomes and that may decrease the duration of treatment for patients with chronic hepatitis C infection," said Brian Woodfall M.D., Vice President of Global Clinical Development at Tibotec. "The company's presence at this year's EASL meeting and the recent launch of the phase 3 clinical trial program for TMC435 reinforce the value of this investigational agent in our growing HCV pipeline."

    The titles of the abstracts and times for Tibotec's presentations on TMC435 appear below – full abstracts can also be accessed at www.easl.eu.

    Oral Presentation:

  • "Impact of IL28B genotype and pretreatment serum IP-10 in treatment-naive genotype-1 HCV patients treated with TMC435 i
    '/>"/>

  • SOURCE Tibotec Pharmaceuticals
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related biology technology :

    1. According to AlphaDetail, Inc. Merck and Tibotec Therapeutics Lead Among Infectious Disease Specialists
    2. 3-D printing method advances electrically small antenna design
    3. SG Biofuels Advances Jatropha Biotech Platform with Application of Genetic Markers to Reference Genome
    4. Redpoint Advances Salt Enhancer Discovery Program
    5. Circassia Initiates Phase II Trials of Novel Grass and Ragweed Allergy Therapies and Advances Phase III Plans for cat Allergy T-Cell Vaccine
    6. Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to Enter Clinical Trials, Into Phase 2 to Treat Patients Infected With Hepatitis C Virus
    7. New treatment for rabies advances after successful phase 1 trial in India
    8. Reportlinker Adds Advances in Biopharmaceutical Technology in China
    9. New Advances in Understanding of Parasite Risk Showcased at CVBD World Forum
    10. MacroGenics Receives NIH Grant Funding of $9.8M for Three Projects; Funding Further Advances DART Platform and Infectious Disease Portfolio
    11. Fulton Project Advances to Phase 2 of Loan Guarantee Process
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... , Jan. 15, 2014 TaiGen Biotechnology Company, Limited ... agreement with R-Pharm, a leading Russian pharmaceutical company, to ... Russian Federation , Turkey ... States (CIS). Nemonoxacin is a novel antibiotic for the treatment ...
    (Date:1/14/2014)... (PRWEB) January 14, 2014 Histogen, Inc., ... products of cells grown under simulated embryonic conditions, today ... agreement with Suneva Medical, Inc. for physician-dispensed aesthetic products ... , This agreement is an amendment to the ...
    (Date:1/14/2014)... 2014 EquitiesIQ, a leading informational research ... Alliqua is an emerging biomedical company acquiring, developing, manufacturing, ... market. , Free report download: http://equitiesiq.com/reports/alliqua/ , ... management team and Board, which launched the company’s new ...
    (Date:1/14/2014)... MA (PRWEB) January 14, 2014 iLab Solutions, ... Detwiler as the new Director of Product Strategy. In this ... well as iLab sub-teams to guide in the development of ... iLab provides the maximum possible benefit to the scientific community ...
    Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2
    ... presentation Sunday, May 17, 8:15 a.m. PDT - - ... p.m. PDT - - Conference call and webcast Tuesday, ... 14 InterMune, Inc. (Nasdaq: ITMN ) today ... presentations related to the company,s pulmonology programs will be presented ...
    ... substantially increased capacity, for continued growth,TORONTO, ... today robust double digit growth in sales, improved cash ... ended March 31, 2009. , In a news release ... 43% growth in the first half of 2009 coupled ...
    ... Dendreon Corporation today announced that Chief Executive Officer, ... Ernst & Young Entrepreneur Of The Year (R) ... Ernst & Young LLP, the awards program recognizes entrepreneurs ... financial performance and personal commitment to their businesses and ...
    Cached Biology Technology:Results From Phase 3 CAPACITY Program of Pirfenidone in IPF and Study of Predictors of Mortality in IPF to be Presented at ATS 2Results From Phase 3 CAPACITY Program of Pirfenidone in IPF and Study of Predictors of Mortality in IPF to be Presented at ATS 3Results From Phase 3 CAPACITY Program of Pirfenidone in IPF and Study of Predictors of Mortality in IPF to be Presented at ATS 4Results From Phase 3 CAPACITY Program of Pirfenidone in IPF and Study of Predictors of Mortality in IPF to be Presented at ATS 5Microbix Sales Grow Over 30% In The Second Quarter; Up 43% In The First Half '09 2Microbix Sales Grow Over 30% In The Second Quarter; Up 43% In The First Half '09 3Microbix Sales Grow Over 30% In The Second Quarter; Up 43% In The First Half '09 4Dendreon Corporation CEO Mitchell H. Gold, M.D. Named Ernst & Young Entrepreneur of the Year(R) 2009 Award Finalist in the Pacific Northwest 2
    (Date:7/9/2014)... 2014) Emerging fungal pathogens pose a greater ... causing population declines of amphibians, bats, corals, bees ... South Florida published in the prestigious journal ... or immunological resistance to a deadly chytrid fungus ... "Acquired resistance is important because it is the ...
    (Date:7/9/2014)... Cancer Genome Atlas (TCGA) Research Network have identified ... lung adenocarcinoma, the most common subtype of lung ... the number of possible therapeutic targets for this ... patients with treatable mutations because many potent cancer ... TCGA is jointly funded and managed by the ...
    (Date:7/9/2014)... shows that some shark species may be able to cope ... with rising temperatures. , The Arctic today is best known ... always like that. Roughly 53 to 38 million years ago ... was more similar to a huge temperate forest with brackish ... of tapirs, hippo-like creatures, crocodiles and giant tortoises. Much of ...
    Breaking Biology News(10 mins):USF study: Amphibians can acquire resistance to deadly fungus 2Study identifies novel genomic changes in the most common type of lung cancer 2Study identifies novel genomic changes in the most common type of lung cancer 3Shark teeth analysis provides detailed new look at Arctic climate change 2Shark teeth analysis provides detailed new look at Arctic climate change 3
    ... on open water to date and other environmental factors led to ... Mexico, concludes a two-year scientific study released today. A team ... of Central Florida in Orlando published their findings in the journal ... years, scientists have been trying to figure out why there were ...
    ... PORTLAND, Ore. Researchers at Oregon Health & Science ... protein strongly linked to ALS (Amyotrophic Lateral Sclerosis) and ... different molecular pathways when genetically manipulated. The findings have ... diseases such as Alzheimer,s and Parkinson,s. ...
    ... For many of us, summer is a time synonymous with ... the United States. In 2011, corn was planted on ... nation continue its trend as the world,s largest exporter of ... desired production levels, most U.S. farmers apply synthetic nitrogen fertilizer ...
    Cached Biology News:Study points to causes of high dolphin deaths in Gulf of Mexico 2Scientists develop new carbon accounting method to reduce farmers' use of nitrogen fertilizer 2Scientists develop new carbon accounting method to reduce farmers' use of nitrogen fertilizer 3
    ... (Ankyrin repeat and SOCS box-containing protein) This ... containing amino acids 75-93 and 348-368 of ... Catalog No. 40149) can be used as ... with mouse and rat Asb-2, based on ...
    ... Rabbit polyclonal to ErbB 2 - ... for all tested applications). ... AENPEYLGLDVPV conjugated to KLH, corresponding to ... Human c-ErbB2 Entrez ...
    SHP-2 Antibody...
    Sheep polyclonal to ErbB 2 ( Abpromise for all tested applications). Antigen: Recombinant full length c-ErbB2 protein (Human). Entrez GeneID: 2064 Swiss Protein ID: P04626...
    Biology Products: